RT Journal Article
SR Electronic
T1 Defining indicators for disease burden, clinical outcomes, policies, and barriers to health services for migrant populations in the Middle East and North African region: a suite of systematic reviews
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.11.23292496
DO 10.1101/2023.07.11.23292496
A1 Seedat, Farah
A1 Evangelidou, Stella
A1 Abdellatifi, Moudrick
A1 Bouaddi, Oumnia
A1 Cuxart-Graell, Alba
A1 Edries, Hassan
A1 Elafef, Eman
A1 Maatoug, Taha
A1 Ouahchi, Anissa
A1 Pampiri, Liv Mathilde
A1 Deal, Anna
A1 Arias, Sara
A1 Assarag, Bouchra
A1 Hassouni, Kenza
A1 Chaoui, Aasmaa
A1 Chemao-Elfihri, Wafa
A1 Hilali, Mahmoud
A1 Ibrahimi, Azeddine
A1 Khalis, Mohamed
A1 Wejdene, Mansour
A1 Mtiraoui, Ali
A1 Wickramage, Kolitha
A1 Zenner, Dominik
A1 Requena-Mendez, Ana
A1 Hargreaves, Sally
A1 the MENA Migrant Health Working Group
YR 2023
UL http://medrxiv.org/content/early/2023/07/12/2023.07.11.23292496.abstract
AB Introduction The Middle East and North Africa (MENA) is characterised by high and complex migration flows, yet little is known about the health of migrant populations, their levels of under-immunisation, and access to healthcare provision. Data are needed to support regional elimination and control targets for key diseases and the design and delivery of programmes to improve health outcomes in these groups. This protocol describes a suite of seven systematic reviews that aim to identify, appraise, and synthesise the available evidence on burden and clinical indicators, policies, and barriers related to these mobile populations in the region.Methods and analysis Seven systematic reviews will cover two questions to explore: 1) the burden and clinical outcomes and 2) the policies, uptake, and the barriers for the following seven disease areas in migrants in the MENA region: tuberculosis, HIV and hepatitis B and C, malaria and neglected tropical diseases, diabetes, mental health, maternal and neonatal health, and vaccine-preventable diseases. We will search electronic databases for studies in any language (year 2000 to 2023), reference-check relevant publications, and cross-check included studies with experts. We will search for grey literature by hand searching key databases and websites (including regional organisations and MoH websites) for country-specific guidelines and talking to our network of experts for local and regional reports and key datasets. We will assess the studies and policies for their quality using appropriate tools. We will meta-analyse the data if they are of sufficient volume and similarity by disease outcome. Where meta-analysis is not possible and where data are on policy, we will narratively synthesise the evidence using summary tables, figures, and text.Ethics and dissemination We anticipate disseminating the findings through peer-reviewed publications, conferences, and other formats relevant to all stakeholders. We are following PRISMA guidelines and protocols will be registered on PROSPERO.STRENGTHS AND LIMITATIONS OF THE STUDYExplicit, transparent, and recommended systematic review methodology.Comprehensive search strategy with no language restrictions and extensive grey literature searching online and through expert government and non-government support.International team with multidisciplinary expertise on migrant health, diseases, policymaking, and methodology.Data prior to the year 2000 will be excluded.Meta-analysis may not be possible due to heterogeneity, and we anticipate that most of the data will come from grey literature.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLa Caixa, LCF/PR/SP21/52930003Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Electronic databases, reference-checking, hand-searching relevant organisational websites and asking experts for further reportsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online in electronic databases or websites.